LivaNova Management
Management criteria checks 1/4
LivaNova's CEO is Vladimir Makatsaria, appointed in Mar 2024, has a tenure of 1.17 years. total yearly compensation is $9.71M, comprised of 8% salary and 92% bonuses, including company stock and options. directly owns 0.008% of the company’s shares, worth €158.00K. The average tenure of the management team and the board of directors is 1.2 years and 3.7 years respectively.
Key information
Vladimir Makatsaria
Chief executive officer
US$9.7m
Total compensation
| CEO salary percentage | 7.96% |
| CEO tenure | 1.2yrs |
| CEO ownership | 0.008% |
| Management average tenure | 1.2yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$222m |
| Dec 31 2024 | US$10m | US$773k | US$63m |
Compensation vs Market: Vladimir's total compensation ($USD9.71M) is above average for companies of similar size in the German market ($USD1.71M).
Compensation vs Earnings: Insufficient data to compare Vladimir's compensation with company performance.
CEO
Vladimir Makatsaria (51 yo)
Mr. Vladimir A. Makatsaria has been the Chief Executive Officer and Director at LivaNova PLC since March 01, 2024. He is a Non-Executive Director of the Health Products Regulatory Authority Board in Irelan...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.2yrs | US$9.71m | 0.0079% € 158.0k | |
| Chief Financial Officer | 4.5yrs | US$2.83m | 0.049% € 983.6k | |
| Senior VP | 2.5yrs | US$2.41m | 0.010% € 208.9k | |
| Chief Innovation Officer | 1yr | US$2.97m | 0% € 0 | |
| President of Cardiopulmonary Business Unit | less than a year | US$2.22m | 0.015% € 300.5k | |
| Senior Director of Investor Relations | no data | no data | no data | |
| Vice President of Corporate Communications | no data | no data | no data | |
| Chief Strategy & Corporate Development Officer | 1.3yrs | no data | no data | |
| Chief Human Resources Officer | less than a year | no data | no data | |
| President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement | no data | no data | no data | |
| President of Global Epilepsy | 5.3yrs | no data | 0.023% € 470.2k | |
| Senior Vice President of APAC & Growth Markets | less than a year | no data | no data |
Experienced Management: LIA's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.2yrs | US$9.71m | 0.0079% € 158.0k | |
| Independent Non-Executive Director | 4.4yrs | US$292.39k | 0.011% € 223.3k | |
| Independent Director | 2.9yrs | US$285.39k | 0.0068% € 137.5k | |
| Chairman of Board | 6.9yrs | US$1.65m | 0.052% € 1.0m | |
| Independent Non-Executive Director | 9.6yrs | US$287.34k | 0.017% € 350.0k | |
| Independent Non-Executive Director | 5.9yrs | US$282.39k | 0.016% € 322.4k | |
| Independent Non-Executive Director | 9.6yrs | US$285.39k | 0.014% € 277.4k | |
| Independent Director | less than a year | US$137.02k | no data | |
| Independent Director | 1.6yrs | US$281.81k | 0.0025% € 50.1k | |
| Independent Director | 2.7yrs | US$270.39k | 0.0064% € 128.0k |
Experienced Board: LIA's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/25 12:31 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LivaNova PLC is covered by 30 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| Michael Polark | Baird |
| Matthew Miksic | Barclays |